<DOC>
	<DOCNO>NCT02870231</DOCNO>
	<brief_summary>This trial conduct United States America . The aim trial investigate Safety , Tolerability , PK ( exposure trial drug body ) PD ( effect investigate drug body ) Multiple Doses NNC9204-0530 Combination Liraglutide Male Female Subjects Overweight Obesity</brief_summary>
	<brief_title>Investigating Safety , Tolerability , PK PD Multiple Doses NNC9204-0530 Combination With Liraglutide Male Female Subjects Being Overweight With Obesity</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Nutrition Disorders</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Body mass index 25.0 39.9 kg/m^2 ( inclusive ) screening . Male female , age 18 55 year ( inclusive ) time sign informed consent Any clinically significant weight change ( equal 5 % selfreported change ) dieting attempt ( e.g . participation organize weight reduction program within last 90 day prior screen Any prior obesity surgery currently present gastrointestinal implant . Thyroidstimulating hormone ( TSH ) value outside 0.46.0 mIU/L Glycosylated haemoglobin ( HbA1c ) equal 6.5 % Syst√®me International ( SI ) unit 48 mmol/mol Abnormal ECG ( electrocardiogram ) result include 2nd 3rd degree AVblock , prolongation QRS complex 120 m , QTcF interval 430 m ( male ) 450 m ( female ) , clinically relevant abnormal result , judge investigator A history additional risk factor Torsades de pointes ( e.g. , heart failure , hypokalaemia , family history Long QT Syndrome ) Personal family history medullary thyroid carcinoma ( MTC ) multiple endocrine neoplasia syndrome type 2 ( MEN 2 ) Calcitonin equal 50 ng/L History pancreatitis ( acute chronic )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>